Abstract Number: 1370 • 2012 ACR/ARHP Annual Meeting
Clinical and Ultrasonographic Features of Nail Disease in Psoriasis and Psoriatic Arthritis
Background/Purpose: The purpose of this study was to investigate the association between clinical and unltrasonographic features of psoriatic nail disease and to identify specific nail…Abstract Number: 1371 • 2012 ACR/ARHP Annual Meeting
Predictors of Erosion-Free Psoriatic Arthritis
Background/Purpose: A number of patients with psoriatic arthritis (PsA) remain erosion-free despite years of disease. We aimed to determine the prevalence, characteristics and predictors of…Abstract Number: 1372 • 2012 ACR/ARHP Annual Meeting
Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). AS significantly affects patients' (pts) work productivity.1 The impact of the…Abstract Number: 1373 • 2012 ACR/ARHP Annual Meeting
Influence of Early Onset On the Clinical Characteristics and Prognosis of Ankylosing Spondylitis
Background/Purpose: To determine the influence of early onset (≤ 16 years) on the clinical characteristics and prognosis of ankylosing spondylitis (AS). Methods: We revised patients…Abstract Number: 1374 • 2012 ACR/ARHP Annual Meeting
Value of C-Reactive Protein Level At Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors
Background/Purpose: To determine the value of acute-phase reactant levels at diagnosis of psoriatic arthritis in predicting the risk of failure of conventional treatment with disease-modifying…Abstract Number: 1375 • 2012 ACR/ARHP Annual Meeting
Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors
Background/Purpose: Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis and has the potential to cause severe joint damage. Research into the prevalence of…Abstract Number: 1336 • 2012 ACR/ARHP Annual Meeting
Changes in the Levels of Anti-Cyclic Citrullinated Protein Antibody and Immunoglobulins in Rheumatoid Arthritis Patients After Administration of Tocilizumab
Background/Purpose: The recently established scoring system of American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) early arthritis diagnosis criteria have assigned scores of 0, 1,…Abstract Number: 1337 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Pharmacokinetic Profile and Its Relationship to Changes in Pharmacodynamic Markers in Patients with Rheumatoid Arthritis
Background/Purpose: Sarilumab, a fully human monoclonal antibody targeting interleukin-6 receptor alpha (IL-6Rα), is being evaluated for the treatment of rheumatoid arthritis (RA) based on the…Abstract Number: 1338 • 2012 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation
Background/Purpose: Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular matrix proteins and…Abstract Number: 1339 • 2012 ACR/ARHP Annual Meeting
A Pilot Study Investigating the Tolerability and Pharmacodynamic Effect of Single Intravenous/Subcutaneous Doses of Olokizumab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Rheumatoid Arthritis
Background/Purpose: Olokizumab is a novel IL-6 inhibitor that selectively blocks the final assembly of the IL-6 signaling complex (gp80+gp130+IL-6). We report the safety, PK, and…Abstract Number: 1340 • 2012 ACR/ARHP Annual Meeting
Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Background/Purpose: Advancements in the understanding of Rheumatoid Arthritis (RA) have led to the development of novel therapeutics and treatment guidelines that target remission as an…Abstract Number: 1341 • 2012 ACR/ARHP Annual Meeting
Beneficial Effect of Anti-TNF Therapy in the Lipoprotein Atherogenic Risk Profile in Comparison with DMARD Standard Therapy in RA Patients
Background/Purpose: RA patients portend a greater risk of cardio-vascular complications than general population. Although most probably diverse mechanisms are implicated, quantity and quality changes in…Abstract Number: 1342 • 2012 ACR/ARHP Annual Meeting
Changes in Patient Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic Naive RA Subjects with Background Methotrexate) Trial
Background/Purpose: Rheumatoid arthritis (RA) is associated with pain, fatigue, disability and functional loss, which can significantly impact a patient's health-related quality of life (HRQoL). Patient-Reported…Abstract Number: 1343 • 2012 ACR/ARHP Annual Meeting
EARLY Improvements in the Lower Limbs Enthesis by Ultrasound Predicting Later Favorable Responses in TNF Inhibotors-Treated Patients with Spondyloarthritis
Background/Purpose: Lower limbs enthesis by ultrasound (US) detects inflammatory activity in patients with spondyloarthritis(SpA) and is a diagnostic tool of early SpA. The present objective…Abstract Number: 1344 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of High Sensitivity C Reactive Protein for Early Axial Spondyloarthritis: Results From the Devenir Des Spondylarthopathies Indifferenciees Recentes Cohort
Background/Purpose: The average delay in spondyloarthritis (SpA) diagnosis after symptom onset is one of the longest among the inflammatory rheumatic diseases. Elevated C-reactive protein (CRP)…